RT10 High Purity Retatrutide Triple Receptor Agonist Peptide For Obesity & Metabolic Disorder Research

Retatrutide brief introduction

Retatrutide  is an innovative triple receptor agonist drug developed by Eli Lilly, used for the treatment of type 2 diabetes and obesity. It targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptor (GCGR), regulating blood sugar and metabolism through multiple mechanisms: enhancing insulin secretion, suppressing appetite, delaying gastric emptying, and promoting fat burning. Clinical trials have shown that Retatrutide may be superior to existing GLP-1/GIP dual-targeted drugs (such as tiraglutide) in terms of lowering blood sugar and weight loss. Currently, it is in the III phase of research and is expected to be another major breakthrough in the field of metabolic treatment.

 Company introduce

Guangzhou Boyuan Outdoor Products Co., Ltd. is a trading company headquartered in Guangzhou, one of southern China's most prominent commercial and logistics hubs. Leveraging the city's well-established supply chain infrastructure and international trade channels, the company has evolved from its original focus on outdoor consumer goods into a specialized supplier of high-purity biochemical reagents and peptide derivatives. While the company retains "Outdoor Products" in its registered name, its current core business centers on providing stable, non-hazardous, and laboratory-grade peptide derivatives to qualified research institutions, universities, and commercial laboratories worldwide.

Boyuan operates under a clear and responsible business philosophy: professionalism, consistency, and traceability. All products offered by the company are positioned strictly as general chemical reagents and laboratory research materials. They are not classified as pharmaceuticals, medical devices, hazardous chemicals, or products intended for human therapeutic, diagnostic, or preventive applications. The company strictly adheres to national and international regulations governing the trade and logistics of non-hazardous chemical products, ensuring that every step—from procurement and quality inspection to warehousing and domestic or international shipping—remains compliant, safe, and fully traceable.

Based on market feedback, Boyuan's products have received high praise from customers, who generally agree that the products have stable purity, rapid reconstitution, good batch-to-batch consistency, and clear advantages in price compared to similar suppliers. Many customers specifically mention Boyuan's professionalism in packaging and logistics, noting that the cold chain packaging is robust with sufficient ice packs, ensuring the product remains in good lyophilized condition even after long-distance transportation. The company has established long-term and stable cooperative relationships with research institutions and distributors from countries such as the United States, Germany, the United Kingdom, Australia, Brazil, and South Korea. Boyuan will continue to develop in the peptide field, enriching its product line, improving quality control standards, optimizing its global logistics network, and actively exploring cooperation opportunities with research institutions. The company plans to introduce more novel peptide products in the future, including but not limited to research molecules such as MOTS-c, SS-31, and FOXO4, while further improving the product traceability system and customer service system. Boyuan believes that through continuous effort and innovation, it can provide global researchers with a better, more convenient, and more reliable experience in sourcing peptide raw materials.